Gene therapy is being investigated in the treatment of lung-related aspects of the genetic disease, Cystic fibrosis (CF). Clinical studies have demonstrated CF transmembrane conductance regulator (CFTR) expression in the airways of adults with CF using a variety of gene transfer agents. In utero gene therapy is an alternative approach that facilitates vector transduction of rapidly expanding populations of target cells while avoiding immune recognition of the vector. In CF, in utero gene transfer could potentially delay the onset of disease symptoms in childhood and compensate for the role, if any, that CFTR plays in the developing organs. Previously published studies have suggested that transient expression of CFTR in utero was sufficient to rescue the fatal intestinal defect in S489X Cftr tm1Unc /Cftr tm1Unc knockout mice. We replicated these studies using an identical CFTR-expressing adenoviral vector and CF mouse strain in sufficiently large numbers to provide robust Kaplan-Meier survival data. Although each step of the procedure was carefully controlled and vector-specific CFTR expression was confirmed in the fetal organs after treatment, there was statistically no significant improvement in the survival of mice treated in utero with AdCFTR, compared with contemporaneous control animals.
IntroductIon
Since the discovery of the gene responsible for Cystic fibrosis (CF), gene therapy strategies have been investigated to treat the progressive lung disease associated with this condition. 1 In utero treatment, a strategy whereby gene transfer agents are delivered to the cells of the developing fetus, has been suggested as an alternative method. The potential advantages of in utero delivery include a reduction in tissue and immunological barriers to gene transfer, and increased access to expanding populations of progenitor or stem cells. 2 In utero gene transfer has been demonstrated in several animal models using a range of delivery strategies 3 but intra-amniotic injection appears to be the most straightforward. In the mouse, gene transfer following intra-amniotic injection of recombinant adenovirus is dependent on the developmental stage of the fetus at the time of injection. After vector delivery at 16 days of gestation (equivalent to a 15-to 20-week gestation period in humans), transgene expression is observed in the lung, stomach and gut and is highly correlated with increased fetal breathing movements. 4 Several CF transgenic mouse strains have been generated in an attempt to model and evaluate potential treatment strategies, but although these mouse models display many of the CF-related ion-transport bioelectric defects found in human CF tissues, lung pathology is not recapitulated. 5 However, some abnormalities of the CF gastrointestinal tract such as intestinal obstruction are observed in mouse models, where they can be very severe, leading to poor survival. 6 The CF knockout mouse strain S489X carrying the Cftr tm1Unc mutation develops intestinal obstruction leading to intestinal perforation, peritonitis and death, resulting in only 5% survival to adulthood, 7 although these mice can survive given the appropriate dietary intervention. 8 Survival of these mice was also reported to increase dramatically when recombinant adenovirus expressing human CF transmembrane conductance regulator (hCFTR) was delivered via intra-amniotic injection to fetal mice in utero. 9 The improved survival was observed even though the adenovirus-mediated CFTR expression was transient, implying that continuous expression of CFTR was not required, therefore challenging the widely held view that it is the absence of the CFTR chloride channel that leads to CF disease in the adult. Thus, it was claimed that by some undefined mechanism, transient CFTR expression during fetal development was sufficient to reverse the lethal intestinal disease permanently. Further studies by the same group reported that overexpression of CFTR during development of wild-type +/+ mice was also lethal 10 and that phenotypic changes in the Cftr −/− intestines and lungs were partially corrected in the rescued knockout mice. 11 These were important observations, not only in the support they leant to the promise of in utero gene therapy for CF, but also because the corollary of this observation is that appropriate CFTR expression in utero is crucial for normal development of fully functional organs at birth. Thus if CFTR plays an essential role in normal development, not only could in utero gene therapy improve the efficiency of gene transfer, but it could also potentially delay the onset of disease symptoms in childhood and compensate for the role, if any, that CFTR plays in the developing organs. Furthermore, if CF is a developmental disease, these findings have major implications for the success, or otherwise, of adult CF gene therapy.
The original study demonstrating in utero correction of the CF mouse intestinal defect 9 raised concerns, 12,13 including questions regarding the small size of the experimental groups leading to the studies being underpowered. The studies presented here were designed to replicate and to control for each aspect of the original study, whilst using statistically rigorous experimental group sizes, in an attempt to independently verify the findings. Generously, the authors of the original study offered their full support. We have confirmed that time-sensitive, intra-amniotic delivery of adenoviral vectors to the murine fetus is straightforward, reproducible and can result in robust transgene expression in the amnion, lungs, and intestines of the developing fetus. However, we were unable to detect a statistically significant improvement in the survival of CFTR treated mice compared with contemporaneous control animals.
results

Bio-distribution of reagents following intra-amniotic injection
The first step of the in utero gene transfer protocol that we aimed to replicate, 9 was to confirm the bio-distribution of gene transfer reagents after delivery to the developing mouse fetus. Preliminary studies were performed using intra-amniotic injection to deliver 0.1 µm red fluorescent microspheres to time-mated C57BL/6 mice at days 14, 16, and 18 of gestation (E14, E16, E18, respectively). Mice were sacrificed 24 hours after injection and the distribution of beads in each pup examined using fluorescence microscopy on cryosections. Intra-amniotic injection at E14 resulted in the detection of substantial quantities of fluorescent beads within the amniotic fluid, but not within the organs themselves (n = 7; Figure 1a and b) . By contrast, delivery at E16 resulted in high levels of fluorescence being detected in the nasal and oral cavities (data not shown) and in both the lungs (7/8) and the intestines (5/8) (Figure 1c and d) . The highest levels of lung (7/7) and intestinal (7/7) fluorescence were observed in fetuses treated at E18 (Figure 1e and f) . No fluorescence was observed in other tissues from treated fetuses, or in any tissues from untreated control fetuses at similar gestational stages. These data confirmed that the gestational timing of injection was important and that intraamniotic injection at E16 of gestation could deliver to the lungs and intestines, the target organs associated with CF disease. Although delivery at E18 led to increased delivery of fluorescent beads, it also resulted in a higher rate of spontaneous abortion (data not shown). In all subsequent experiments, we utilized E16 as the time of intra-amniotic delivery in line with the original studies.
9,10
Gene expression following intra-amniotic delivery of adenoviral vectors The next step was to quantify reporter gene expression following injection of the recombinant adenoviral vector AdLuc [10 6 to 10 ( Figure 3a) and iodide-efflux assay (Figure 3b) , the AdCFTR vector was delivered to fetuses from time-mated S489X Cftr tm1Unc mice at E16 (10 8 pfu/fetus) and the level of hCFTR-specific mRNA quantified in the lungs and intestines 48 hours after injection. As all treated fetuses resulted from heterozygote matings, the genotype of each treated fetus was also determined. We showed that the resultant level of hCFTR mRNA was similar for all genotypes in both the lungs (Figure 3c ) and intestines ( Figure 3d ) (P > 0.157, MannWhitney U). Importantly, no hCFTR-specific mRNA expression was detected in the lungs or intestines of any pups of any genotype from control S489X Cftr tm1Unc litters that were untreated.
effect of hcFtr expression on survival of cftr −/− mice Any conclusion regarding the effectiveness of in utero hCFTR expression in correcting the lethal intestinal defect in S489X Cftr tm1Unc /Cftr tm1Unc mice will be wholly dependent on the number of Cftr −/− mice surviving after injection of AdCFTR compared with injection of control AdLacZ vector. Therefore each step in the procedure was controlled to ensure that the survival of each mouse was due only to the treatment, rather than any confounding factor in the husbandry or genotyping of the mice. First we improved the published genotyping assay, 14 which tended to have poor discriminatory power in our hands, by developing a multiplex, real-time TaqMan PCR assay that reliably determined genotypes even when using small parts of semi-cannibalized pups as source material (data not shown). Importantly, rather than relying on historical values, we assessed the survival of untreated litters in parallel to provide contemporaneous survival data in our facility. We observed that ~20% of Cftr −/− mice routinely survived into adulthood (70 days) even in the absence of the low-residue liquid diet often used to increase Cftr −/− survival. 8 This 20% level of survival contrasts with published reports of only 5%, 14 but was consistent over a period of 2-3 years and remained so at the time of the study (see survival of untreated mice in Table 1) .
Finally, to assess the impact of in utero delivery of AdCFTR on the survival of Cftr −/− mice, S489X litters were injected at E16 Litters from heterozygote S489X matings were injected with AdLacZ or AdCFTR at 16 days of gestation. The total number of litters treated, the number of individual fetuses injected and the eventual number of pups detected at birth were recorded for each treatment group. Data for "lost" animals represent fetuses that were resorbed before birth, or cannibalized at birth before litter size was determined. Tissue samples from surviving mice or dead pups were used to determine the number of mice of each genotype at birth (Day 0) and the number of mice of each genotype surviving at 100 days after birth. Unknown genotypes represent pups that were born but could not be genotyped due to maternal cannibalism within the first few days of life.
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In Utero CF Table 1 ; P = 0.047 paired t-test] and reflects fetuses that were either resorbed before birth, or cannibalized on the day of birth before litter size was determined. The frequency of such "lost" or missing fetuses did not appear to be related to treatment type as a similar percentage was noted for each of the three treated groups [7.8, 12. 3, and 5.9% for the AdLacZ (10 7 ), AdCFTR ( 10 7 ), and AdCFTR (10 8 ), respectively; Table 1 ] and was also similar in other mouse strains such as C57BL/6 (data not shown). Mothers and offspring were monitored daily with any deaths recorded and tissue samples removed from deceased animals for genotyping wherever possible. It was not possible to determine the genotype of a small number of pups due to complete maternal cannibalism, but this did not appear to be related to treatment as it occurred with a similar frequency in all four experimental groups [1.3, 6.9, 5.0, and 1.0% for untreated, AdLacZ (10 7 ), AdCFTR ( 10 7 ), and AdCFTR (10 8 ), respectively; Table 1 ]. At 21 days, surviving offspring were weaned from their mother and tissue samples taken to determine the Cftr genotype and surviving offspring were monitored up to 100 days after birth.
In the untreated control group, high levels of mortality were observed for all genotypes shortly after birth, with 33% of Cftr −/− pups dying within 3 days compared with 19% of +/− and 22% of +/+ pups (Figure 4a) . Following this initial critical period, few additional deaths were observed with 80% of +/− and 79% of +/+ mice surviving beyond the end of the study at 100 days. By contrast, only 16% of −/− pups survived beyond the end of the study (Figure 4a ) with 63% dying before weaning at 21 days. Crucially, in utero administration of adenoviral vectors expressing hCFTR resulted in no significant improvement in survival of Cftr −/− mice to 100 days (Figure 4b) . Kaplan-Meier estimates of the median survival age for 10 7 or 10 8 pfu/fetus AdCFTR-treated groups and the AdLacZ control group, were 9 ± 7.8, 2 ± 2.3, and 7 ± 6.7 days, respectively, similar to the 13 ± 2.5 days noted for the untreated group. In all four experimental groups the majority of Cftr −/− deaths (~80-85%) occurred in the first 4 weeks after birth, although a modest number (~10-15%) in each treatment group survived beyond the end of the study at 100 days. Surviving −/− animals demonstrated the "white teeth" phenotype commonly observed in homozygous CF mice 15 and were much smaller than surviving +/− and +/+ littermates (P = 0.0005; analysis of variance) with a mean weight (at day 70) of 21.0 ± 1.0 g compared with 25.4 ± 0.3 g and 25.0 ± 0.4 g in +/− and +/+ mice (data from all groups combined). Crucially, the log rank survival test revealed no significant difference in survival between the four experimental groups of Cftr −/− animals (P = 0.71). Therefore, in this study in utero treatment with adenoviral vectors expressing hCFTR did not enhance survival of CF animals compared with contemporaneous control animals.
dIscussIon
We have confirmed that intra-amniotic injection at E16 of gestation allows access to the developing organs of the murine fetus (Figure 1 ) and that delivery of recombinant adenoviral vectors can lead to expression of luciferase reporter gene (Figure 2 ) and hCFTR mRNA (Figure 3 ) in fetal lungs and intestines. However, there was statistically no significant improvement in the survival of Cftr −/− mice after AdCFTR treatment, compared with contemporaneous control animals (Figure 4) . Therefore, despite careful replication, we were unable to verify the observation that expression of hCFTR in the fetal intestine could correct the lethal intestinal defect in the CF knockout mouse as described in an earlier study. 9 Inspection of the ratio of Cftr −/−, +/−, and +/+ genotypes observed in the various treatment groups at birth ( Table 1) , revealed a departure from the expected 1:2:1 Mendelian distribution in both the untreated and the AdLacZ-treated groups (P = 0.034 and 0.0004, respectively, χ 2 ). By contrast, no deviation from a Mendelian genotype distribution was observed in the AdCFTR ( 10 7 ) or AdCFTR (10 8 ) treated groups. One interpretation is that treatment with AdCFTR led to increased in utero survival of Cftr −/− fetuses as argued previously. 10 However other plausible explanations exist. The observed non-Mendelian distribution of genotypes between groups might be explained by pups lost to genotyping after complete maternal cannibalism, and/or by the fact that genotype distributions of the experimental groups at the time of treatment may not have been equivalent, or by chance alone. Support for these alternative explanations comes from the observation that the genotype distributions observed in the AdCFTR ( 10 7 ) and AdCFTR (10 8 ) treated groups were not significantly different from those observed in the untreated control group (P = 0.151 and 0.137, respectively, χ 2 ). Table 1. www.moleculartherapy.org vol.16no.5may2008
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Larson and colleagues also reported treatment-dependent alterations in the expected Mendelian ratio of Cftr +/− and +/+ mice. 10 In their untreated population, they observed an excess of Cftr +/+ progeny (from untreated heteozygote matings) that survived >75 days, such that the ratio was closer to 1:1 (Cftr +/− to +/+) rather than 2:1 as expected from Mendelian inheritance. 10 A similar 1:1 ratio was also observed after AdLacZ treatment, though the numbers of animals reported were too low to be statistically powerful. 10 However, after AdCFTR treatment, the number of Cftr +/− and +/+ animals surviving >75 days was closer to 10:1. The authors' interpretation was that in utero AdCFTR treatment had two distinct effects: firstly, the correction of the lethal intestinal phenotype in Cftr −/− mice, and secondly, a decreased survival of Cftr +/+ mice due to a hyperplastic lung proliferative disorder. 10 While we did not measure the lung pathology of the Cftr +/+ mice in our treatment groups, our survival data ( Table 1 and Figure 4) did not reproduce the AdCFTR dependent changes in Cftr +/− to +/+ ratio that they observed.
It was unfortunate that the S489X Cftr tm1Unc mouse strain demonstrated such high levels of maternal cannibalism and neglect leading to a high mortality of newborn pups of all genotypes, especially following surgical interventions. Losses were reduced by transferring mice onto a high protein breeders' diet, but to minimize the impact of nonspecific deaths upon the survival study, a series of exclusion criteria were incorporated into the study design such that data from the entire litter were excluded if no pups were born, or the entire litter was eaten, or if the entire litter died within the first week of life. Thus large numbers of litters were excluded from both control and treatment groups, but sufficient litters were treated to allow statistical analysis of survival with enough power to identify any treatment-associated increase in survival ( Table 1) .
It is formally possible that minor technical differences between our study and that of Larson et al. 9 could explain the difference in results obtained. For example, the accurate calculation of gestational age can be difficult to confirm and small differences in the timing of the intra-amniotic injection could be crucial to subsequent intestinal development. It is also possible that there were inconsistencies in the calculation of the adenoviral vector titre causing an under-or overestimation of the final dose administered. In the original study 10 8 pfu/fetus of AdCFTR were delivered, 9 but later publications from the same group suggested that a dose of 10 7 pfu/fetus was also sufficient 10 ; we observed no difference in survival outcome following the delivery of 10 7 or 10 8 pfu AdCFTR and neither did the authors of the accompanying paper when an injected dose of 10 8 or 2 × 10 9 pfu/fetus was used. 16 Although methods for calculating the potency (pfu/ml) of a viral preparation may vary between laboratories, the range of doses investigated here seems likely to be sufficient to reveal any dose-dependent differences.
An important difference is the ~20% survival of the Cftr −/− mice observed in our facility compared with a previously reported 5%. 14 The intestinal pathology and mortality in CF transgenic mouse models can vary dependent on the precise Cftr knockout mutation, environmental influences and the independent segregation of modifier genes. 6, 17 The survival chances of one CF mouse model Cftr tm1G551D /Cftr tm1G551D were shown to vary between 27 and 67% depending on undetermined environmental factors in the animal breeding facility. 18 Interestingly, when we transferred a subset of our S489X Cftr −/− mice to an alternative animal facility they died of intestinal obstruction within a few days (data not shown). Together these observations suggest that survival is a problematic end point to utilize reliably in CF mice.
An additional and potentially confounding issue is the genetic heterogeneity in the transgenic mouse strain. Unavoidably, our studies used S489X Cftr tm1Unc CF knockout mice as a 10th generation backcross onto to C57BL/6 background, as opposed to a 5th generation backcross. 10 In the accompanying paper, Buckley et al. 16 attempted independent verification of the original study, using the same adenoviral vector, but using an alternative knockout CF mouse allele (Cftr tm1Cam /Cftr tm1Cam ) on an inbred genetic background (129 S6Sv/Ev) to minimize genetic heterogeneity and the effects of potential modifier genes. However, the authors were also unable to demonstrate improved survival of Cftr −/− mice following intra-amniotic injection of AdCFTR.
We have, to the best of our ability, replicated the original in utero gene transfer study of Larson and Cohen. We used identical surgical methods and adenoviral vectors, along with a population of CF mice that was as similar as possible; we also secured the support of the original authors for our approach. We have demonstrated the feasibility and success of each stage in the procedure, but were still unable to confirm that transient in utero expression of CFTR in the developing intestines of the CF mouse was sufficient for improved survival. This could be due to problems with the design of the original study, including the use of death as an end-point in a mouse strain where survival is susceptible to genetic heterogeneity and environmental factors. Finally, although adenoviral vectors appear to transduce a range of tissues after in utero delivery, in the absence of integration, these vectors will ultimately be diluted out following successive rounds of cell proliferation in the developing fetus. Thus alternative vectors capable of integration and/or persistent gene expression will be required if in utero gene therapy is to be investigated further for correction of genetic diseases.
MAterIAls And MetHods
Animal model. The Cftr-mutant UNC mouse strain, S489X (Cftr Genotyping. Genomic DNA was extracted from tail biopsies at weaning, or from tissue taken from animals that died before weaning, using Qiagen DNeasy kit (Qiagen, Crawley, UK). Genotyping was performed using an ABI PRISM 7700 Sequence Detector (TaqMan) (Applied Biosystems, Warrington, UK) utilizing primer and fluorogenic probe combinations specific to murine Cftr exon 10 and to the inserted neomycin gene contained in the mutant allele. Genomic DNA (~250 ng) was analyzed in a 25 µl multiplex reaction containing 1× Universal PCR Master Mix (Applied Biosystems) and primer/probe combinations for the simultaneous detection of both alleles. Detection of the wild-type allele utilized mCFTR exon 10-1283F 5′-TTGGTGTTTCCTATGATGAGTACAGAT-3′ (300 nmol/l) and mCFTR exon 10-1381R 5′-AGCTAACACAATCAGCATTTTTC ATAA-3′ (300 nmol/l) primers and the mCFTR exon 10-1317B probe VIC-5′ TACCTGCTGTAGTTGGCAAGCTTTGACAACA 3′-TAMRA
